January 21, 2008

Gilead Announces Departure of Caroline Dorsa

John F. Milligan, PhD, Reassumes Role of Chief Financial Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 21, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Caroline Dorsa has resigned from her position as Chief Financial Officer (CFO), a role she assumed in November 2007, to pursue another opportunity.

Gilead plans to initiate a search to identify a new CFO. In the interim, John F. Milligan, PhD, Gilead's Chief Operating Officer, will reassume the additional responsibilities of CFO - a position he held from 2003 until 2007 - effective immediately.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.

CONTACT: Gilead Sciences, Inc. Susan Hubbard, 650-522-5715 (Investors) Amy Flood, 650-522-5643 (Media) SOURCE: Gilead Sciences, Inc.

Investors

Jacquie Ross
investors_relations@gilead.com

Media Contact

Meaghan Smith
public_affairs@gilead.com

Other News

Some of the content on this page is not intended for users outside the U.S.